Vera Therapeutics, Inc.
Support and Resistance Levels
Past performance
News About VERA
All events for VERA
All deals for VERA
Financial Ratios
Financial Statements
VERA vs Sector & Peers
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020. Website veratx.com
Headquarters Brisbane, CA, US